Skip to content


  • Poster presentation
  • Open Access

Evaluation of molecular model-based discovery of ecto-5’-nucleotidase inhibitors on the basis of X-ray structures

  • 1 and
  • 1
Journal of Cheminformatics20146 (Suppl 1) :P13

  • Published:


  • Adenosine
  • Virtual Screening
  • Docking Study
  • Site Region
  • Binding Characteristic

Ecto-5’-nucleotidase (e5NT) belongs to the family of metallophosphoesterases, hydrolyses AMP to adenosine, and is a regulator of the adenosine signaling pathway [1]. It has been shown, that free adenosine is involved in various diseases and cancer progression [2, 3]. In a previous study, a molecular model of e5NT has been created and used for the identification of new sulfonamide inhibitors [4]. Recently, X-ray structures of human e5NT in complex with different inhibitors were published [5]. This made it possible to reevaluate the model building and virtual screening efforts in detail. An extensive analysis of the comparative e5NT model, built using a bacterial enzyme in the presence of 35% sequence identity as a template, showed that the model was topologically correct and had high accuracy within the active site region. Comparative docking studies were carried out to explore inhibitor binding characteristics within the X-ray structure and the model. The results provided plausible explanations for the successful identification of new e5NT inhibitors by model-based virtual screening and highlighted important parameters [6].

Authors’ Affiliations

Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Dahlmannstrasse 2, D-53113 Bonn, Germany


  1. Zimmermann H, Zebisch M, Sträter N: Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signalling. 2012, 8: 437-502. 10.1007/s11302-012-9309-4.View ArticleGoogle Scholar
  2. Deaglio S, Robson SC: Ectonucleotidases as regulators of purinergic signalling in thrombosis, inflammation, and immunity. Adv Pharmacol. 2011, 61: 301-332.View ArticleGoogle Scholar
  3. Zhang B: CD73: a novel target for cancer immunotherapy. Cancer Res. 2010, 70: 6407-6411. 10.1158/0008-5472.CAN-10-1544.View ArticleGoogle Scholar
  4. Ripphausen P, Freundlieb M, Brunschweiger A, Zimmermann H, Müller CE, Bajorath J: Virtual screening identifies novel sulfonamide inhibitors of ecto-5‘-nucleotidase. J Med Chem. 2012, 55: 6576-6581. 10.1021/jm300658n.View ArticleGoogle Scholar
  5. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Müller CE, Sträter N: Crystal structure of the human ecto-5’-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure. 2012, 20: 2161-2173. 10.1016/j.str.2012.10.001.View ArticleGoogle Scholar
  6. Furtmann N, Bajorath J: Evaluation of molecular model-based discovery of ecto-5’-nucleotidase inhibitors on the basis of X-ray structures. Bioorg Med Chem.Google Scholar


© Furtmann and Bajorath; licensee Chemistry Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.